Kelly; Marcus

Patent Applications and Registrations

Patent applications and USPTO patent grants for Kelly; Marcus.The latest application filed is for "radiolabeled anti-pd-l1 antibodies for immuno-pet imaging".

Company Profile

9.8.15

Kelly; Marcus - New York NY

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Trademarks

Patent Activity

Patent	Date
Radiolabeled Anti-pd-l1 Antibodies For Immuno-pet Imaging App 20220184241 - Kelly; Marcus ; et al.	2022-06-16
Tubulysins And Protein-tubulysin Conjugates App 20210260208 - HAN; Amy ; et al.	2021-08-26
Anti-egfrviii Antibodies And Uses Thereof App 20210147557 - KIRSHNER; Jessica R. ; et al.	2021-05-20
Radiolabeled Anti-lag3 Antibodies For Immuno-pet Imaging App 20210138096 - Kelly; Marcus ; et al.	2021-05-13
Radiolabeled Met Binding Proteins For Immuno-pet Imaging App 20210077638 - Kelly; Marcus ; et al.	2021-03-18
Anti-MUC16 antibodies Grant 10,941,208 - Haber , et al. March 9, 2	2021-03-09
Methods of treating PRLR positive breast cancer Grant 10,925,971 - Kelly , et al. February 23, 2	2021-02-23
Radiolabeled anti-LAG3 antibodies for immuno-PET imaging Grant 10,905,784 - Kelly , et al. February 2, 2	2021-02-02
Radiolabeled Anti-pd-l1 Antibodies For Immuno-pet Imaging App 20200345872 - Kelly; Marcus ; et al.	2020-11-05
Anti-MUC16 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Molecules that Bind MUC16 and CD3, and Uses Thereof App 20200317810 - Haber; Lauric ; et al.	2020-10-08
Anti-EGFRvIII antibodies and uses thereof Grant 10,738,124 - Kirshner , et al. A	2020-08-11
Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof Grant 10,738,130 - Haber , et al. A	2020-08-11
Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging Grant 10,736,976 - Kelly , et al. A	2020-08-11
ANTI-EGFRvIII ANTIBODIES AND USES THEREOF App 20180312594 - KIRSHNER; Jessica R. ; et al.	2018-11-01
Radiolabeled Anti-lag3 Antibodies For Immuno-pet Imaging App 20180228926 - Kelly; Marcus ; et al.	2018-08-16
Anti-EGFRvIII antibodies and uses thereof Grant 10,047,160 - Kirshner , et al. August 14, 2	2018-08-14
Methods Of Treating Prlr Positive Breast Cancer App 20180185504 - Kelly; Marcus ; et al.	2018-07-05
Radiolabeled Anti-pd-l1 Antibodies For Immuno-pet Imaging App 20180161464 - Kelly; Marcus ; et al.	2018-06-14
Anti-MUC16 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Molecules that Bind MUC16 and CD3, and Uses Thereof App 20180118848 - Haber; Lauric ; et al.	2018-05-03
Anti-MUC16 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Molecules that Bind MUC16 and CD3, and Uses Thereof App 20180112001 - Haber; Lauric ; et al.	2018-04-26
Anti-EGFRvIII antibodies and uses thereof Grant 9,475,875 - Kirshner , et al. October 25, 2	2016-10-25
ANTI-EGFRvIII ANTIBODIES AND USES THEREOF App 20160304615 - KIRSHNER; Jessica R. ; et al.	2016-10-20
ANTI-EGFRvIII ANTIBODIES AND USES THEREOF App 20150259423 - KIRSHNER; Jessica R. ; et al.	2015-09-17

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.